Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
April 29, 2021 09:30 ET | Source: PAVmed Inc. PAVmed Inc.
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE)
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally recognized healthcare executive Jacque J. Sokolov to its Board of Directors (the “Board”). Dr. Sokolov will help establish and serve as the inaugural Chair of the Board’s new Compliance & Quality Committee. He will also serve on Lucid’s Audit and Compensation Committees.
“I am delighted to welcome Jacque Sokolov to Lucid’s Board of Directors,” said Lishan Aklog M.D., Lucid’s Executive Chairman and PAVmed’s Chairman and Chief Executive Officer. “Jacque brings remarkable breadth of experience
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
PAVmed Inc.April 29, 2021 GMT
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally recognized healthcare executive Jacque J. Sokolov to its Board of Directors (the “Board”). Dr. Sokolov will help establish and serve as the inaugural Chair of the Board’s new Compliance & Quality Committee. He will also serve on Lucid’s Audit and Compensation Committees.
First published on
Encouraged by the development of rapid at-home coronavirus tests, medtech companies are now betting on the potential to sell over-the-counter and direct-to-consumer diagnostics for diseases beyond COVID-19.
The pandemic has enabled consumers to get tested for the virus in the privacy of their homes, a convenience that companies like Abbott Laboratories and Quest Diagnostics are hoping will appeal to people when it comes to other diagnostics.
Home testing was already rising worldwide, as consumers take a more proactive role in their healthcare. COVID-19 is likely speeding that shift, analysts and companies say. Home testing and home collection will fundamentally reshape the diagnostics industry and healthcare in general by providing more testing options, said William Blair analysts, who contend that OTC tests will be one of the key long-term impacts of the pandemic on the industry.
FDA waiver broadens the use of chlamydia and gonorrhea test at more point-of-care settings news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Modern Healthcare Illustration / Getty Images
With rapid antigen tests for SARS-CoV-2 slow to come to market, officials at the US Food and Drug Administration have tried to signal via a number of public comments that the agency would be flexible regarding test performance requirements and use models.
These indications of flexibility have largely failed to speed development and commercialization of rapid antigen tests, however, as test vendors, wary of falling short of agency requirements, have instead stuck to the more stringent specifications presented in the FDA s test templates.
Early in the COVID-19 pandemic, rapid antigen tests were identified as a potentially key technology for slowing transmission of SARS-CoV-2 with calls for these tests growing as it became evident that molecular test capacity was not able to keep up with demand and was unlikely to ever reach a level where regular testing at population scale would be possible.